| Identification | More | [Name]
Quipazine | [CAS]
4774-24-7 | [Synonyms]
2-PIPERAZIN-1-YL-QUINOLINE
QUIPAZINE
TIMTEC-BB SBB011283
1-(2-quinolinyl)piperazine
1-(2-quinolyl)piperazine
2-(1-piperazinyl)-quinolin
2-(1-piperazinyl)quinoline
QUIPAZINE DIMALEATE (2-(1-PIPERAZINYL)QU I | [EINECS(EC#)]
227-314-2 | [Molecular Formula]
C13H15N3 | [MDL Number]
MFCD00242605 | [Molecular Weight]
213.28 | [MOL File]
4774-24-7.mol |
| Hazard Information | Back Directory | [Uses]
antineoplastic | [Definition]
ChEBI: 2-(1-piperazinyl)quinoline is a member of pyridines and a member of piperazines. | [Synthesis]
Step 1: Piperazine (10.20 g, 2.45 mmol) was dissolved in 15 mL of isopropanol in a dry round-bottomed flask under nitrogen protection. Subsequently, 2-chloroquinoline (0.20 g, 1.2 mmol) was added and the reaction mixture was heated and stirred at reflux for 24 hours. After completion of the reaction, water was added to the mixture and extracted with ethyl acetate. The organic layers were combined, washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the solvent. The crude product obtained was purified by silica gel column chromatography with eluent ratio of dichloromethane:methanol=4:1 to afford the target compound 2-(piperazin-1-yl)quinoline in 36% yield. | [in vivo]
Quipazine (2.5, 5 and 7.5 mg/kg, one dose for once; i.p.) affects dietary self-selection of different macronutrient diets in male and female rats[1]. | [References]
[1] Patent: EP1724267, 2006, A1. Location in patent: Page/Page column 35; 68
[2] Journal of Medicinal Chemistry, 2010, vol. 53, # 21, p. 7549 - 7563
[3] Journal of Pharmaceutical Sciences, 1992, vol. 81, # 1, p. 99 - 103
[4] Chemical and Pharmaceutical Bulletin, 2001, vol. 49, # 10, p. 1314 - 1320
[5] Patent: WO2004/46124, 2004, A1. Location in patent: Page 41 |
|
| Company Name: |
NovoChemy Ltd.
|
| Telephone: |
86-(0)21-31261262 373522135 |
| Website: |
www.novochemy.com |
|